Evidence map›Paper›PMID 41233394›Full record

ArticleScientific reports2025

An international 20 country patient and physician survey of the usability and acceptability of Stepped Care pathway in Parkinson's disease.

K Poplawska-Domaszewicz, C Rodriguez-Blazquez, I Boura, L Batzu, V Metta, V Leta, Kit Wu, A Shalash, M Chengjiei, H S Dafsari and 40 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors.

K Poplawska-DomaszewiczDepartment of Neurology, Poznan University of Medical Sciences, Poznan, Poland. karolina.poplawska@usk.poznan.pl.
C Rodriguez-BlazquezNational Centre of Epidemiology and CIBERNED, Institute of Salud Carlos III, Madrid, Spain.
I BouraSchool of Medicine, University of Crete, Heraklion, Crete, Greece.
L BatzuParkinson's Centre of Excellence, Kings College Hospital, London, UK.
V MettaParkinson's Centre of Excellence, Kings College Hospital, London, UK.
V LetaParkinson's Centre of Excellence, Kings College Hospital, London, UK.
Kit WuParkinson's Centre of Excellence, Kings College Hospital, London, UK.
A ShalashDepartment of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
M ChengjieiDepartment of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, China.
H S DafsariFaculty of Medicineand, Department of Neurology, University Hospital Cologne, University of Cologne, Cologne, Germany.
W JostParkinson-Klinik Ortenau GmbH & Co KG, Kreuzbergstr, Wolfach, Germany.
J ChackoDepartment of Neurology, Welcare Hospital, Kochi, Kerala, India.
A RekikDepartment of Neurology of Sahloul Hospital, Sousse, Tunisia.
C PadmakumarOlder Person Medical Clinic, Broadmeadow, NSW, Australia.
Y H LauDivision of Neurology, Medical Department, Hospital Tengku Ampuan Rahimah, Klang, Selangor, Malaysia.
C Falup PecurariuDepartment of Neurology, Faculty of Medicine, County Clinic Hospital, Transilvania University Brasov, 500019, Brasov, Romania.
T LoneyCollege of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health, Dubai, United Arab Emirates.
Hani T S BenamerCollege of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health, Dubai, United Arab Emirates.
D UrsoParkinson's Centre of Excellence, Kings College Hospital, London, UK.
G LogroscinoCenter for Neurodegenerative Diseases and the Aging Brain, Department of Clinical Research in Neurology, University of Bari 'Aldo Moro', "Pia Fondazione Cardinale G. Panico", Tricase, Lecce, Italy.
C SpanakiSchool of Medicine, University of Crete, Heraklion, Crete, Greece.
W KozubskiDepartment of Neurology, Poznan University of Medical Sciences, Poznan, Poland.
S MichalakDepartment of Neurology, Division of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, Poznan, Poland.
A PisaniDepartment of Brain and Behavioral Sciences, University of Pavia, IRCCS Mondino Foundation, Pavia, Italy.
R van CollerDepartment of Neurology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
D TrivediDementech Clinical Neuroscience Academic Centre, Wimpole Street, London, UK.
J SlawekDepartment of Neurological-Psychiatric Nursing, Faculty of Health Sciences, Medical University of Gdansk, Gdansk, Poland.
A SauerbierParkinson's Centre of Excellence, Kings College Hospital, London, UK.
D KoziorowskiDepartment of Neurology, Faculty of Health Sciences, Medical University of Warsaw, Warsaw, Poland.
S GangadharanParkinson's Disease Clinic for the Older Person, John Hunter Hospital, Rankin Park Centre, Newcastle, Australia.
K L KohDepartment of Neurology, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.
C Lazcano-OcampoDepartment of Neurology, Parkinson Centre (CENPAR), Los Conquistadores 1963, Santiago, Chile.
P OdinDivision of Neurology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Y TsuboiDepartment of Neurology, Long-Term Observation Research, Juntendo University, Tokyo, Japan.
M G KrambergerDepartment of Neurology, University Medical Center Ljubljana, Medical Faculty, Ljubljana University of Ljubljana, Ljubljana, Slovenia.
N MostynKings Parkinson Charity, London, UK.
V GoyalInstitute of Movement Disorders and Parkinson's Centre, Medanta Hospitals, New Delhi, India.
R MridulaParkinson's Disease and Movement Disorders Research Centre, Citi Neuro Centre, Hyderabad, India.
S MuzerengiDepartment of Clinical Neurosciences, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Trust, Birmingham, B15 2TH, UK.
S Ben AmorDepartment of Neurology of Sahloul Hospital, Sousse, Tunisia.
L K PrashanthCenter for Parkinson's Disease and Movement Disorders, Manipal Hospital, Bangalore, India.
A AntoniniParkinson and Movement Disorders Unit, Centre for Rare Neurological Diseases (ERN-RND), Department of Neuroscience, University of Padua, Padua, Italy.
I SubramanianDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
M Rodriguez-ViolanteClinical Laboratory of Neurodegenerative Diseases, INNNMVS, Mexico City, Mexico.
M TagliatiDepartment of Neurology, Cedars-Sinai Medical Center, Los Angeles, USA.
S DesaiShree Krishna Hospital, Pramukhswami Medical College, Bhaikaka University, Karamsad, Anand, Gujarat, India.
C S SankhlaDepartment of Neurology, P D Hinduja National Hospital and Research Centre, Mumbai, India.
R BorgohainParkinson's Disease and Movement Disorders Research Centre, Citi Neuro Centre, Hyderabad, India.
P Martinez-MartinCentre for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain.
K Ray ChaudhuriParkinson's Centre of Excellence, Kings College Hospital, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is not a single condition and has multiple heterogeneous presentations with several endophenotypes as well as collateral factors affecting care and health. However, clinical consultations globally often miss these important aspects in clinic. The Stepped Care pathway of care was developed from PD patients' opinion and attempts to combine these gaps in care in a simple 3-stage clinical paradigm. We conducted a survey across twenty (20) countries to explore the views of clinicians and PD patients on the process, acceptability and need of the Stepped Care pathway. A structured questionnaire was administered in both affluent and under-resourced clinics, capturing data from a multi-ethnic and diverse patient base. 99% patients (White, Asian and Black) felt Stepped Care toolkit asked relevant questions addressing needs and concerns in PD care that are often missed, and 96% agreed with the importance of using this toolkit during Outpatient Clinic visits. Moreover, a significant majority of PD patients (96%) felt Stepped Care makes them understand their condition better. 92% of clinicians indicated that the Stepped care toolkit could be an effective asset in clinical practice, while 91% of clinicians agreed that the toolkit provides holistic care which is often missed in clinic. This novel global survey of the efficacy and useability of Stepped Care for PD is overwhelmingly endorsed by PD patients and clinicians from a diverse, multi-ethnic background across high- and low- income countries. Stepped Care can be used in clinical practice in order to ensure a holistic and comprehensive care for PD.

Indexed as

Parkinson DiseasePatient Acceptance of Health CarePhysiciansAgedFemaleHumansMaleMiddle AgedSurveys and QuestionnairesDashboardHolistic careNonmotor subtypesNonmotor symptomsParkinson’s disease.Stepped Care

Identifiers

PMID41233394
PMCPMC12615761

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.